Previous 10 | Next 10 |
Moleculin Biotech to Present at the Virtual Investor Innovations in Acute Myeloid Leukemia (AML) Spotlight Event PR Newswire – Live moderated video webcast with members of management to discuss its ongoing Phase 1/2 study of core technology in development, Annam...
Moleculin Selected to Present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care PR Newswire HOUSTON , Sept. 8, 2022 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinic...
Moleculin to Present at the H.C. Wainwright 24th Annual Global Investment Conference PR Newswire HOUSTON , Sept. 7, 2022 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical ...
Seres Therapeutics, Inc. ( NASDAQ: MBRX ), a biotech focused on microbiome therapeutics, added ~7% in the pre-market trading Wednesday after the company announced the completion of the rolling submission process seeking FDA approval for its lead asset SER-109. With the...
The U.S. Food and Drug Administration (FDA) granted orphan drug designation to Moleculin Biotech's ( NASDAQ: MBRX ) WP1122 to treat Glioblastoma Multiforme (GBM), a type of brain cancer. "Given the progress of our Phase 1 clinical trial in healthy volunteers, the stron...
Moleculin Receives FDA Orphan Drug Designation of WP1122 for the Treatment of Glioblastoma Multiforme PR Newswire - Glioblastoma is the most aggressive malignant primary brain tumor with serious unmet medical need HOUSTON , Sept. 6, 2022 /PRNewswi...
Moleculin Announces Completion of Third Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK PR Newswire – Preliminary results of third cohort in the first-in-human Phase 1a allows Company to proceed to next single ascending dose (SA...
Moleculin Biotech press release ( NASDAQ: MBRX ): Q2 GAAP EPS of -$0.24. The Company ended the quarter with $58.0 million of cash. The Company believes that this cash is sufficient to meet its projected operating requirements, which include a forecasted increase ...
Moleculin Reports Second Quarter 2022 Financial Results and Provides Programs Update PR Newswire - Continued advancement across clinical and preclinical programs; on track with multiple milestones and key data readouts expected through the second half of 2022 -...
Moleculin Concludes Phase 1b and Opens Recruitment in Phase 2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases PR Newswire – Preliminary Phase 1b data demonstrated clinical activity, defined as stable disease or better ...
News, Short Squeeze, Breakout and More Instantly...
Moleculin Biotech Inc. Company Name:
MBRX Stock Symbol:
NASDAQ Market:
Moleculin Biotech Inc. Website:
Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML PR Newswire HOUSTON , July 10, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfoli...
2024-06-17 10:10:00 ET June 17, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at developments for the treatment of blood cancers. Today's snapshot focuses in on acute myeloid leukemia (AML) and the compan...
Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial PR Newswire – 89% of CRc's were subjects with "poor prognosis" cytogenetics and/or mutations – Current median durability of response (mDOR) of CRc's = 6 months and in...